Feifei Wang
Impact in
- Cancer Research top 5%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Molecular Biology top 10%
- Extracellular vesicles in disease
- Circular RNAs in diseases
- RNA modifications and cancer
Papers in
-
- Ubiquitin and proteasome pathways 5
- Epigenetics and DNA Methylation 4
- Oncology 10
- Cytokine Signaling Pathways and Interactions 2
- Cancer Immunotherapy and Biomarkers 2
- Peptidase Inhibition and Analysis 2
- Co-authors
- Yanqing Ding (10 shared papers)Liang Li (9 shared papers)Xiaoli Ren (7 shared papers)Wenting Liao (5 shared papers)Zhicheng Zeng (5 shared papers)Jinlong Hu (3 shared papers)Fuyao Song (3 shared papers)Xiaohui Zhu (4 shared papers)
- Journals
- Cell Death and Disease (3 papers)Cancer Immunology Immunotherapy (2 papers)Oncogene (2 papers)PLoS ONE (2 papers)Advances in Clinical and Experimental Medicine (1 paper)
- Partner nations
- ChinaAustraliaUnited States
In The Last Decade
Feifei Wang
29 papers receiving 1.2k citations
Feifei Wang's Hit Papers
Peers
Comparison fields: 5 of 104
- Cancer Research 617
- Molecular Biology 878
- Oncology 253
- Immunology 171
- Immunology and Allergy 24
Countries citing papers authored by Feifei Wang
This map shows the geographic impact of Feifei Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Feifei Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Feifei Wang more than expected).
Fields of papers citing papers by Feifei Wang
This network shows the impact of papers produced by Feifei Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Feifei Wang. The network helps show where Feifei Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Feifei Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 30 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis Hit paper breakdown → | 2018 | 738 |
| 2 | 2019 | 49 | |
| 3 | 2022 | 37 | |
| 4 | 2019 | 32 | |
| 5 | 2015 | 32 | |
| 6 | 2019 | 29 | |
| 7 | 2021 | 26 | |
| 8 | 2021 | 22 | |
| 9 | 2020 | 22 | |
| 10 | 2013 | 20 | |
| 11 | 2013 | 18 | |
| 12 | 2020 | 17 | |
| 13 | 2017 | 17 | |
| 14 | 2022 | 15 | |
| 15 | 2015 | 15 | |
| 16 | 2014 | 14 | |
| 17 | 2022 | 13 | |
| 18 | 2018 | 10 | |
| 19 | 2020 | 10 | |
| 20 | 2018 | 8 |
About Feifei Wang
Feifei Wang is a scholar working on Molecular Biology, Oncology, Cancer Research, Immunology and Small Animals, having authored 30 papers that have together received 1.2k indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (5 papers), Epigenetics and DNA Methylation (4 papers), Geology and Paleoclimatology Research (3 papers), Cytokine Signaling Pathways and Interactions (2 papers), Cancer Immunotherapy and Biomarkers (2 papers), Cancer Mechanisms and Therapy (2 papers), Peptidase Inhibition and Analysis (2 papers) and MicroRNA in disease regulation (2 papers). The work is most often cited by research in Cancer Research (617 citations), Molecular Biology (878 citations), Oncology (253 citations), Immunology (171 citations) and Immunology and Allergy (24 citations). Feifei Wang has collaborated with scholars based in China, Australia and United States. Frequent co-authors include Yanqing Ding, Liang Li, Xiaoli Ren, Wenting Liao, Zhicheng Zeng, Jinlong Hu, Fuyao Song, Xiaohui Zhu, Xiao-Liang Lan and Wei Yang. Their work appears in journals such as Cell Death and Disease, Cancer Immunology Immunotherapy, Oncogene, PLoS ONE and Advances in Clinical and Experimental Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.